How to Launch Products in a Virtual World

Education is the highest form of marketing. Shannon Maverick sets on out on a quest to speak with business leaders from around B2B to better understand how they are utilizing education with their customers.

 

Product launches in the B2B realm traditionally occurred at trade shows. These events offered exposure but also a lot of competition for eyes. Once COVID-19 hit, the event industry collapsed, leaving companies to pivot on launching products digitally. As always, Maverick of Marketing wanted to provide listeners with tips on marketing in a virtual world. Host Shannon Maverick welcomed AtlasIED’s VP of Marketing, Gina Sansivero, to discuss its successful campaign of introducing its audience to the Atmosphere platform.

First, Sansivero talked about her journey with AtlasIED. “I’ve been with the company over two years. At that time, the son of the owner took over the company and wanted to refresh with new people and energy,” she said.

In her second year at the company, she faced what every marketer did—the coronavirus. The business was hyping up the new product for debut at InfoComm, the biggest show for AV. Two months before the event, the association moved it to virtual.

“We had to pivot quickly from the traditional marketing we were doing to get traffic to the booth,” Sansivero said.

The company decided it didn’t want to launch its product at InfoComm virtual and went about planning its own live event, which included renting a closed theater and hiring live event professionals. Sansivero also went back to the product owner to see if there was anything else they could add to the platform since they had more time.

AtlasIED tried some new channels for promoting the live event and generated a huge buzz. Their registration numbers were much larger than the leads they captured at their last InfoComm, and attendance was over 50% for those registered.

“We had an audience focused exclusively on our product launch. Ultimately, the cost per lead was less than half of what it would have been at InfoComm,” Sansivero said.
As for the future, Sansivero understands that part of the success was a captive audience at home.

However, she noted they were reducing their footprint at upcoming shows, and the product attracted a lot of attention.

“Sales benefitted from the momentum, and we weren’t lost in the noise of InfoComm. They were able to engage people and help them visualize how the product would work through virtual demos,” she added.

Check on the live launch for Atmosphere here.

Listen to Previous Episodes of Maverick of Marketing Right Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More